The overall goals of the Center are to: (1) Provide better access to standard laboratory analyses and facilities; (2) assist in recruitment of study patients with diabetes and suitable controls, and provide complex animal models such as primates for diabetes-related investigation; (3) foster the development and efficient use of new technologies relevant to diabetes research; (4) coordinate, stimulate and support collaborative studies between investigators interested in diabetes at the U of Washington; and (5) enhance the environment for research training of post doctoral fellows and predoctoral medical and basic science students interested in Diabetes and related metabolic and endocrine disorders. To accomplish these goals the Diabetes Endocrinology Research Center is organized around six core units: Administrative Core, Clinical Research Core, Cytohistochemistry Core, Immunoassay Core, Physiology Core and Tissue Culture Core. Through specific services provided,, these cores support the research of over 40 Affiliate investigators and 36 Associate investigators. This research covers the entire spectrum of diabetes investigation including (a) molecular, cellular and physiological regulation of metabolic hormones and the mechanism of hormone action, (b) etiology and pathogenesis of IDDM and NIDDM, (c) mechanism of hyperlipidemia and the role of lipoproteins in atherosclerosis, (d) etiology, pathogenesis, treatment and prevention of diabetic complications and (e) etiology and pathogenesis of obesity. In addition, the Center's Pilot and Feasibility and Molecular Studies Development Programs provide initial support for new investigators in the field of diabetes, new diabetes research by established investigators in other disciplines and encourages the application of molecular biology to problems in the field of diabetes. To enhance the scientific environment for diabetes research at the University of Washington, the Center's Enrichment Program provides a Seminar Series, Core Symposia, and Visiting Scientist Program.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
3P30DK017047-25S1
Application #
6502806
Study Section
Special Emphasis Panel (ZDK1 (O1))
Program Officer
Abraham, Kristin M
Project Start
1977-06-01
Project End
2002-11-30
Budget Start
2000-12-01
Budget End
2001-11-30
Support Year
25
Fiscal Year
2001
Total Cost
$152,000
Indirect Cost
Name
University of Washington
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Tanaka, Shigeru; Pfleger, Christian; Lai, Jen-Feng et al. (2018) KAP1 Regulates Regulatory T Cell Function and Proliferation in Both Foxp3-Dependent and -Independent Manners. Cell Rep 23:796-807
Houston, Denise K; Neiberg, Rebecca H; Miller, Michael E et al. (2018) Physical Function Following a Long-Term Lifestyle Intervention Among Middle Aged and Older Adults With Type 2 Diabetes: The Look AHEAD Study. J Gerontol A Biol Sci Med Sci 73:1552-1559
Guo, Rui; Hua, Yinan; Ren, Jun et al. (2018) Cardiomyocyte-specific disruption of Cathepsin K protects against doxorubicin-induced cardiotoxicity. Cell Death Dis 9:692
van Zuydam, Natalie R; Ahlqvist, Emma; Sandholm, Niina et al. (2018) A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes. Diabetes 67:1414-1427
Hull, Rebecca L; Gibson, Ronald L; McNamara, Sharon et al. (2018) Islet Interleukin-1? Immunoreactivity Is an Early Feature of Cystic Fibrosis That May Contribute to ?-Cell Failure. Diabetes Care 41:823-830
Koletzko, Sibylle; Lee, Hye-Seung; Beyerlein, Andreas et al. (2018) Cesarean Section on the Risk of Celiac Disease in the Offspring: The Teddy Study. J Pediatr Gastroenterol Nutr 66:417-424
Roe, Nathan D; Handzlik, Michal K; Li, Tao et al. (2018) The Role of Diacylglycerol Acyltransferase (DGAT) 1 and 2 in Cardiac Metabolism and Function. Sci Rep 8:4983
Chepurny, Oleg G; Bonaccorso, Ron L; Leech, Colin A et al. (2018) Chimeric peptide EP45 as a dual agonist at GLP-1 and NPY2R receptors. Sci Rep 8:3749
Wang, Yang; Sosinowski, Tomasz; Novikov, Andrey et al. (2018) C-terminal modification of the insulin B:11-23 peptide creates superagonists in mouse and human type 1 diabetes. Proc Natl Acad Sci U S A 115:162-167
Kikuchi, Shinsuke; Chen, Lihua; Xiong, Kevin et al. (2018) Smooth muscle cells of human veins show an increased response to injury at valve sites. J Vasc Surg 67:1556-1570.e9

Showing the most recent 10 out of 1296 publications